dabigatran etexilate (Pradaxa) -

dabigatran etexilate (Pradaxa)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cardiovascular system disorders
Summary
The SMC has accepted dabigatran etexilate (Pradaxa®) for use within NHS Scotland for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Cost-effectiveness of longer-term use (>18 months) is uncertain.
UKMi comment
NICE guidance on the use of dabigatran for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism is currently under development (publication date TBC).
Related links: NICE guidance in development